Group items matching

in title, tags, annotations or url

A new report, published by the Office of National Statistics (ONS), has revealed worrying statistics about the mental health of children and young people in England. The report is based on NHS survey on Mental Health of Children and Young People in England 2023, which showed that one in five children and young individuals aged eight to 25 were grappling with probable mental disorders. The report highlighted that 20.3 per cent of eight to 16-year-olds showed signs of mental distress in 2023. Among 17 to 19-year-olds, the proportion rose to 23.3 per cent, while in 20 to 25-year-olds, it stood at 21.7 per cent. The rates of probable mental disorders were similar for boys and girls, while for 17- to 25-year-olds, rates were twice as high for young women than young men.

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries. This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain. Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company. Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines. Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

The microfluidics market is valued at 8.28 Billion in 2017 and is expected to grow at a CAGR of 22.6% during the forecast period, to reach to USD 27.91 Billion by 2023. Base year considered for the report is 2017 and the forecast period includes 2018 to 2023. The increasing incidence of other major chronic and infectious diseases, coupled with advancements in coagulation tests, blood gas electrolytes, hematology, urine chemistry, and cardiac markers, are creating new avenues for the growth of the POC diagnostics market. This, in turn, is expected to support the growth of the microfluidics market as POC testing is the largest segment of the microfluidics market for in vitro diagnostics.

HayMax, manufacturer of organic, drug-free allergen barrier balms for hay fever, dust, and pet allergies, has recently won the 2023 Global 100 awards. The HayMax balm, applied around nostril rims and eye bones, is an innovative allergen blocker against pollen, dust, and pet allergens entering the body. Independent university research confirms it traps over a third of pollen, along with dust mites and pet dander, before they enter the body, according to HayMax. The drug-free balm is Soil Association-certified organic, comprising 100 per cent natural ingredients. Safe for children, pregnant, and breastfeeding women, it holds the Vegetarian Society Approved trademark. This award has come as a complete surprise to us at HayMax," said HayMax MD, Max Wiseberg. "Being held in such high regard through this global recognition is truly delightful." "The Global 100 aims to offer readers insight into firms that excel in their chosen specialties, and the award underscores hard work and innovation of various companies," said its organisers.

Pharmacy Business will be hosting their annual awards event in the pharmacy calendar with a glittering ceremony to celebrate the very best of community pharmacy. The 23rd edition of the Pharmacy Business Awards will be on Wednesday 4 October 2023 in central London. The awards attract the biggest names in pharmacy, with heads of pharmacy organisations, CEOs of leading manufacturers and wholesalers, health officials and government ministers in attendance. We look forward to bringing together the shining lights of community pharmacy, who show the nation the unique services they continue to provide. REASONS TO ATTEND Understand what the ambitions of the NHS and PSNC are for the future of community pharmacy Understand why its important to develop a wider range of health services Learn how others are achieving this and what the benefits can be Learn what the benefits of embracing technological innovations are Hear what others are doing and what the benefits are to their business Network with and learn from your peers in community pharmacy WHO SHOULD ATTEND? Pharmacy owners Pharmacy managers Other pharmacy stakeholders Exciting news! Pharmacy Business Awards 2023 are just around the corner!

The latest inspection report of the General Pharmaceutical Council (GPhC) revealed that nine pharmacies did not meet their standards out of 52 pharmacies that were inspected between January 2023 and May 2023. Pharmacies are inspected on five principles - Governance, Staff, Premises, Services including medicines management and Equipment and facilities. Out of nine, eight pharmacies did not meet GPhC standard of governance which is defined to safeguard the health, safety and wellbeing of patients and the public. Six pharmacies did not meet the GPhC standard of principle four which defines the way in which pharmacy services, including the management of medicines and medical devices, are delivered safeguards the health, safety and wellbeing of patients and the public. The purpose of these standards is to create and maintain the right environment, both organisational and physical, for the safe and effective practice of pharmacy. The standards apply to all pharmacies registered with GPhC.

NHS England has urged the pharmacy owners to continue to voluntarily submit New Medicine Service (NMS) quarterly summary data to the NHS Business Services Authority (NHSBSA) for Quarter 4 (Q4) 2022/23 (January to March 2023). Community Pharmacy England have agreed with NHS England that the quarterly returns will continue to be on a voluntary basis, with Q4 (January to March 2023) as the second quarter to be reported. It has thanked all the members that submitted NMS quarterly summary data for Quarter 3. The mandatory requirement to submit this data has been suspended since 2020, due to the COVID-19 pandemic. "NHS England wants to continue collection of the quarterly returns to provide baseline data to support a long-term evaluation that will be conducted as part of ongoing work to expand the scope of NMS," said Community Pharmacy England. Voluntary submissions can be made via the NHSBSA website, where an updated reporting spreadsheet is also available for head offices to use who are able to submit data on behalf of multiple pharmacies.

The Global Pediatric Neurology Summit in New York 2023 is the premier event for pediatric neurologists from around the world. Learn more about new research and treatments, and discover the latest advancements in pediatrics neurology. Register today to join us.

The Pharmaceutical Services Negotiating Committee (PSNC) has launched Pharmacy Pressures Survey 2023 to make case against the 'unprecedented financial and operational challenges' faced by the community pharmacies in England. The Committee has urged those working in or owns a community pharmacy to 'take part' in the survey. "The survey results will be critical to help us to show Government and the NHS how difficult things now are for pharmacies, and to persuade them to take action. We will be using the results in our negotiations, in our conversations with MPs, Ministers and in national media work as part of the joint #saveourpharmacies campaign," said PSNC. The Pharmacy Pressures Survey is once again comprised of two surveys to give insight into both financial and operational pressures. Together with the other national pharmacy organisations PSNC are working both to show policy makers the severity of the problems and to lobby for Government and NHS action to ease the pressures.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

Join us for the prestigious Pharmacy Business Awards 2023, celebrating excellence in community pharmacy. Attend the glittering ceremony in London and witness industry leaders, officials, and ministers. Submit your entry now and showcase the unique services of community pharmacy. Nomination deadline: July 7th, 2023.

Join us at the 23rd edition of the Pharmacy Business Awards on Wednesday, October 4, 2023, in central London. This prestigious event honors the very best of community pharmacy, attracting industry leaders, heads of organizations, and government officials. Showcasing the unique services provided by community pharmacies, submit your entries by July 7, 2023, for a chance to be recognized in one of our award categories. Don't miss this opportunity to celebrate excellence in pharmacy and make your mark in the industry.

The NHS has made major improvements across long waits, urgent and emergency services, and cancer care, latest performance figures published on Thursday (11) have shown. The number of patients waiting more than 18 months fell to 10,737 by April - down by more than 90 per cent from 124,911 in September 2021 and by more than four-fifths since the start of January when there were 54,882. Around half of NHS trusts in England have no patients on their elective care waiting lists apart from those who have chosen to wait longer. More than one in five (21%) trusts had completely eliminated 18-month waits. However, the overall waiting list has risen to over 7.3 million entries in England. "I promised I would cut NHS waiting lists and we are delivering," Prime Minister Rishi Sunak said. "Reducing 18-month waits by over 90 per cent is huge progress, and it is testament to the hard work of NHS staff who have achieved this despite one of the busiest winters on record. "We still have work to do, but backed by record government investment and the ongoing efforts of the NHS, I am confident we will get patients the care they need more quickly." Ambulance response rates have improved to their fastest in two years, with average category two response times now at 28.5 minutes and category one at 8 mins. The 62-day cancer backlog has fallen for the first time since before the pandemic, with those waiting two months or more down from 21,823 at the end of the last financial year (March 2022) to 19,248 at the end of this March (2023). This is down almost 15,000 from a peak of 34,000 in July 2022.

Emergency Medicine & Acute Care 2023 Course will be able to effectively translate the strategies into improved diagnostics and implement a better treatment plan for their patients.

The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter. The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2). UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University, analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023. Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader community. The sample will be structured to broadly reflect key population characteristics.

Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England regarding medicine pricing issues reported by pharmacy owners (its members). A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month. Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price. The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

Johnson & Johnson has made it to the list of top 10 most innovative companies in the world released by FOREX.com. The US-based pharmaceutical company is the fourth most innovative company, scoring 8.23/10 in the innovation index. Johnson & Johnson is the only pharmaceutical company making it to top 10 list, which makes it the world's most innovative pharmaceutical company in 2023. The ranking is based on many factors such as the number of US-registered patents in 2022, the number of R&D expenses over the last 12 consecutive months and their last reported intangible assets. The health giant spent £37.16 billion on intangible assets (the second highest after Apple), £11.87 billion on R&D last year and registered 1,377 patents last year.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

Professor Michael Gordon Scott and Professor Charlotte Anne Skitterall have been recognised in the New Year Honours list 2023 for their 'service to pharmacy'. Professor Scott Director, Medicines Optimisation Innovation Centre was one among the 1,107 people to received MBE for his 'service to pharmacy' in Northern Ireland. In 1994 he established the first academic practice unit in the province in conjunction with the Queens University of Belfast. In 2004 he was made a fellow of the Pharmaceutical Society of Northern Ireland. In June 2009 he was made an honorary Professor of Pharmacy Practice at QUB. Professor Skitterall, Group Chief Pharmacist, Manchester University NHS Foundation Trust received MBE for 'services to Pharmacy'. Last year, she was appointed as a Fellow of the Royal Pharmaceutical Society. "I think it was awarded in recognition of the work I have done as chair of the National Medicines Optimisation Clinical Reference Group. I also supported the National Pharmacy Task and Finish Group for Covid Vaccine deployment," she commented. This year, dozens of NHS staff have been recognised in the New Year Honours list ahead of the health service's 75th birthday.

Swiss generic drugmaker Sandoz said on Thursday that it would pay $265 million (£209m) to settle a pricing antitrust case in the US. Under the agreement, Sandoz is resolving all damages claims without admitting to any wrongdoing in the case brought in the US state of Pennsylvania. "Under the terms of the agreement, Sandoz US will pay $265 million in exchange for a full release of all claims asserted against it in the direct purchaser class action by the settlement class members," the company said in a statement, adding that the payment would be incorporated into 2023 results. Sandoz became an independent company in October 2023, following the spinoff from Novartis. "As a new public company, this settlement underscores the Sandoz commitment to integrity and sound governance, and is an encouraging step toward putting allegations of legacy conduct behind us", it said in its statement.